KLTO

MKT CAP:$21M

Klotho Neurosciences, Inc.

Market Cap

$21M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$0.35+$0.03 (+8.26%)

Apr 14, 2026

Company Details

Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or preventi...

CEO

Joseph A. Sinkule

IPO Date

Apr 29, 2022

Website

klothoneuro.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$11M

EPS (Diluted)

-$0.33

Free Cash Flow

-$6M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q3 2025

Sep 29, 2025

$0EPS -$0.05

Q2 2025

Jun 30, 2025

$0EPS -$0.12

Q1 2025

Mar 31, 2025

$0EPS -$0.08

FY 2024

Dec 31, 2024

$0EPS -$0.32

Q4 2024

Dec 31, 2024

$0EPS -$0.08

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 23	$0	$0	-$244.3K
Q3 23	$0	$0	-$123.7K
Q4 23	$0	$0	-$110.7K
Q1 24	$0	$0	-$672.0K
Q2 24	$0	$0	-$395.6K
Q3 24	$0	$0	-$3M
Q4 24	$0	$0	-$2M
Q1 25	$0	$0	-$2M
Q2 25	$0	$0	-$2M
Q3 25	$0	$0	-$2M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 23	$107.5K	$107.5K
Q3 23	-$27.0K	-$27.0K
Q4 23	-$199.5K	-$199.5K
Q1 24	-$22.0K	-$145.5K
Q2 24	-$424.9K	-$424.9K
Q3 24	-$1M	-$1M
Q4 24	-$944.2K	-$944.1K
Q1 25	-$2M	-$2M
Q2 25	-$2M	-$2M
Q3 25	-$1M	-$1M

Capital Expenditures

Quarter	CapEx
Q2 23	$2
Q3 23	$3
Q4 23	$0
Q1 24	$123.5K
Q2 24	$3
Q3 24	$0
Q4 24	$4
Q1 25	$0
Q2 25	$1
Q3 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 24	—	+62.0%
Q3 24	—	+2220.2%
Q4 24	—	+1572.2%
Q1 25	—	+136.1%
Q2 25	—	+378.5%
Q3 25	—	-35.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 23	$0	—
Q3 23	$100.0K	—
Q4 23	-$100.0K	—
Q1 24	$287.3K	—
Q2 24	$0	—
Q3 24	$2M	—
Q4 24	$659.2K	—
Q1 25	$495.5K	—
Q2 25	$390.2K	—
Q3 25	$639.6K	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q2 23	—	$244.3K	—
Q3 23	—	$123.7K	—
Q4 23	—	$110.7K	—
Q1 24	—	—	$672.0K
Q2 24	—	$395.6K	—
Q3 24	—	$3M	—
Q4 24	—	$2M	—
Q1 25	—	$2M	—
Q2 25	$238.7K	$2M	—
Q3 25	$271.1K	—	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 23	$40.4K	$0	$40.4K
Q3 23	$2.1K	$0	$2.1K
Q4 23	$2.8K	$0	$2.8K
Q1 24	$32.3K	$0	$32.3K
Q2 24	$845.3K	$0	$845.3K
Q3 24	$50.9K	$0	$50.9K
Q4 24	$63.7K	$0	$63.7K
Q1 25	$565.9K	$0	$565.9K
Q2 25	$8M	$0	$8M
Q3 25	$7M	$0	$7M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 23	1.04B	—	—
Q3 23	1.04B	0.0%	—
Q4 23	1.04B	0.0%	—
Q1 24	1.04B	0.0%	—
Q2 24	16M	-98.5%	-98.5%
Q3 24	17M	+6.4%	-98.4%
Q4 24	27M	+62.3%	-97.4%
Q1 25	28M	+1.6%	-97.4%
Q2 25	34M	+23.4%	+116.5%
Q3 25	59M	+75.0%	+256.0%

Shares Outstanding